当前位置： SCI文献检索 > CANCER GENE THERAPY期刊下所有文献 > Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas.

Adenovirus-mediated overexpression of Fas induces apoptosis of gliomas.

Abstract：

:Gliomas express a higher amount of Fas than normal brain tissue. It is of interest to know whether expression of the Fas receptor is unfavorable to the antiapoptotic pathways in gliomas. In this study, we introduced the Fas gene via an adenovirus vector (Adeno-Fas) into the A-172, U251, and U-373 MG glioma cell lines, each of which expresses Fas on the cell surface. Infection of Adeno-Fas induced apoptosis in each glioma cell line. In U251 cells and A-172 cells that express the same level of Fas as a result of infection with Adeno-Fas, a much higher percentage of U251 cells underwent apoptosis than did A-172 cells. This suggests that each glioma cell line has its own threshold of Fas expression, above which apoptosis is induced, and that the constitutive expression of Fas is below the level of this threshold. It was found that the constitutive expression of the anti-apoptotic gene Bcl-X(L) is higher in A-172 cells than in U251 cells. Adenovirus-mediated transduction of the Bcl-X(L) gene into U251 cells effectively suppressed Adeno-Fas-mediated apoptosis. These data indicate that the Bcl-X(L) gene is one of the important determinants of the threshold for Fas-mediated apoptosis. When U251 and U-373 MG cells were transduced with the Fas gene controlled by the myelin basic protein promoter, which had been shown to be active in gliomas but not in neural tissues, the cells underwent markedly enhanced apoptosis. Taken together, these results indicate that the overexpression of Fas alone induced apoptosis in each glioma cell line. The degree of Fas-mediated apoptosis was attenuated by the expression of an anti-apoptotic gene, Bcl-X(L). The adenovirus-mediated induction of Fas gene controlled by a tissue-specific promoter (e.g., myelin basic protein promoter) would be a promising therapeutic approach for malignant glioma.

journal_name

Cancer Gene Ther

journal_title

Cancer gene therapy

authors

Shinoura N,Ohashi M,Yoshida Y,Kirino T,Asai A,Hashimoto M,Hamada H

doi

10.1038/sj.cgt.7700110

subject

Has Abstract

pub_date

2000-02-01 00:00:00

pages

224-32

issue

2

eissn

0929-1903

issn

1476-5500

journal_volume

7

pub_type

杂志文章

相关文献

CANCER GENE THERAPY文献大全
  • Development of an oncolytic herpes simplex virus using a tumor-specific HIF-responsive promoter.

    abstract：:We exploited the differential activation of hypoxia-inducible factor (HIF)-dependent gene expression in tumors versus normal tissue for the design of a targeted oncolytic herpes simplex virus type-1 (HSV-1). A gene that is essential for viral replication, infected cell polypeptide 4 (ICP4), was placed under the regula...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.62

    authors： Longo SL,Griffith C,Glass A,Shillitoe EJ,Post DE

    更新日期：2011-02-01 00:00:00

  • In vivo manipulation of interleukin-2 expression by a retroviral tetracycline (tet)-regulated system.

    abstract：:We have used the tetracycline (tet)-regulated system as described previously to evaluate the applicability of controlled gene expression in cancer gene therapy. As a model gene, we used the human interleukin-2 (IL-2) gene, which has been placed under the transcriptional control of the tetO/promoter. Human melanoma cel...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700021

    authors： Pitzer C,Schindowski K,Pomer S,Wirth T,Zöller M

    更新日期：1999-03-01 00:00:00

  • Correction: Specific driving of the suicide E gene by the CEA promoter enhances the effects of paclitaxel in lung cancer.

    abstract：:An amendment to this paper has been published and can be accessed via a link at the top of the paper. ...

    journal_title：Cancer gene therapy

    pub_type： 已发布勘误

    doi：10.1038/s41417-020-0166-y

    authors： Ballesteros ARR,Hernández R,Perazzoli G,Cabeza L,Melguizo C,Vélez C,Prados J

    更新日期：2020-06-01 00:00:00

  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy.

    abstract：:A number of monoclonal antibodies (mAbs) have been studied for their ability to enhance immune responses. Although these antibodies are effective in pre-clinical and clinical studies, they are costly and have occasionally been associated with adverse effects such as autoimmunity and cytokine storm. Numerous studies ha...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2009.39

    authors： Boczkowski D,Lee J,Pruitt S,Nair S

    更新日期：2009-12-01 00:00:00

  • Neuregulin receptor-mediated gene transfer by human epidermal growth factor receptor 2-targeted antibodies and neuregulin-1.

    abstract：:The human epidermal growth factor receptors 2, 3, and 4 (HER2, HER3, and HER4, respectively) are frequently overexpressed in many human cancers, and therefore may be potential targets for receptor-mediated gene transfer. To evaluate this possibility, we constructed a series of HER-targeted gene transfer vehicles by co...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700069

    authors： Kern JA,Wakita R,Sliwkowski MX

    更新日期：1999-11-01 00:00:00

  • Use of targeted cationic liposomes in enhanced DNA delivery to cancer cells.

    abstract：:Cationic liposomes are considered to be safe vectors for gene transfer, but they are less efficient at delivering DNA to cells when compared with retroviral vectors. Cationic liposomes complexed with DNA were targeted to specific cells in vitro by means of monoclonal antibodies (mAbs) or ligands associated with the li...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Kao GY,Change LJ,Allen TM

    更新日期：1996-07-01 00:00:00

  • Anticancer activity of oncolytic adenovirus vector armed with IFN-alpha and ADP is enhanced by pharmacologically controlled expression of TRAIL.

    abstract：:We have previously described oncolytic adenovirus (Ad) vectors KD3 and KD3-interferon (IFN) that were rendered cancer-specific by mutations in the E1A region of Ad; these mutations abolish binding of E1A proteins to p300/CBP and pRB. The antitumor activity of the vectors was enhanced by overexpression of the Adenoviru...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7701107

    authors： Shashkova EV,Kuppuswamy MN,Wold WS,Doronin K

    更新日期：2008-02-01 00:00:00

  • Growth of human melanoma xenografts is suppressed by systemic angiostatin gene therapy.

    abstract：:The effect of local and systemic delivery of the angiostatin gene on human melanoma growth was studied in nude mice. Liposome-coated plasmids carrying the cDNA coding for murine and human angiostatin (CMVang and BSHang) were injected weekly, locally or systemically, in mice transplanted with melanoma cells. The treatm...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700331

    authors： Rodolfo M,Catò EM,Soldati S,Ceruti R,Asioli M,Scanziani E,Vezzoni P,Parmiani G,Sacco MG

    更新日期：2001-07-01 00:00:00

  • Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase.

    abstract：:A recombinant adenovirus expressing Escherichia coli cytosine deaminase (AdCD) was constructed with the purpose of exploring its utility for the treatment of breast cancer. Infection of the human breast cancer cell line, MDA-MB-231, with AdCD resulted in high levels of cytosine deaminase enzyme activity. MDA-MB-231 ce...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：

    authors： Li Z,Shanmugam N,Katayose D,Huber B,Srivastava S,Cowan K,Seth P

    更新日期：1997-03-01 00:00:00

  • The chicken chorioallantoic membrane tumor assay as model for qualitative testing of oncolytic adenoviruses.

    abstract：:Oncolytic adenoviruses are promising anticancer agents. To study and optimize their tumor-killing potency, genuine tumor models are required. Here we describe the use of the chicken chorioallantoic membrane (CAM) tumor model in studies on oncolytic adenoviral vectors. Suspensions of human melanoma, colorectal carcinom...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2011.68

    authors： Durupt F,Koppers-Lalic D,Balme B,Budel L,Terrier O,Lina B,Thomas L,Hoeben RC,Rosa-Calatrava M

    更新日期：2012-01-01 00:00:00

  • MicroRNA21 and the various types of myeloid leukemia.

    abstract：:Myeloid leukemia (ML) is heterogeneous cancer classified by abnormal growth of myeloid cells due to genetic aberrations and mutations. It is generally categorized by clonal disorders of hematopoietic stem cells and differentiation. The molecular mechanism behind the myeloid malignancies is not yet known, but recent se...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-018-0025-2

    authors： Panagal M,S R SK,P S,M B,M K,Gopinathe V,Sivakumare P,Sekar D

    更新日期：2018-08-01 00:00:00

  • Bone marrow stromal cells-derived microRNA-181-containing extracellular vesicles inhibit ovarian cancer cell chemoresistance by downregulating MEST via the Wnt/β-catenin signaling pathway.

    abstract：:Cisplatin (DDP)-based strategies are the first-line treatment for cancers; however, resistance to DDP remains a major obstacle to cancer treatment. The current study set out to investigate the effects of microRNA-181c (miR-181c) on the resistance of ovarian cancer cells to DDP. Ovarian cancer-associated miRs as well a...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-020-0195-6

    authors： Ruan Z,Lu L,Zhang L,Dong M

    更新日期：2020-07-07 00:00:00

  • TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.

    abstract：:Immune checkpoint inhibition (ICI) has revolutionized cancer treatment, and produced durable responses in many cancer types. However, there remains a subset of patients that do not respond despite their tumors exhibiting PD-L1 expression, which highlights the need for additional biomarkers relevant to response. Here, ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/s41417-020-0174-y

    authors： Choucair K,Morand S,Stanbery L,Edelman G,Dworkin L,Nemunaitis J

    更新日期：2020-12-01 00:00:00

  • Adenovirus-mediated p16INK4 gene transfer significantly suppresses human breast cancer growth.

    abstract：:The p16INK4 tumor suppressor gene encodes a protein that inhibits cyclin-dependent kinase 4, and its homologous deletion is common in human breast cancer. p16INK4 gene transfer has been reported to be efficacious in inducing growth inhibition of various human tumors such as brain, lung, prostate, and esophageal cancer...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700226

    authors： Campbell I,Magliocco A,Moyana T,Zheng C,Xiang J

    更新日期：2000-09-01 00:00:00

  • Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.

    abstract：:The gene transfer of tumor-specific chimeric immunoglobulin T-cell receptors (cIgTCRs) combining antibody-like specificity with the effector cell function could be an attractive tool in immunotherapy. In this study, we directed the human natural killer (NK) cell line YT to tumor cells by gene transfer of a cIgTCR with...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700453

    authors： Schirrmann T,Pecher G

    更新日期：2002-04-01 00:00:00

  • Immune properties of recombinant vaccinia virus encoding CD154 (CD40L) are determined by expression of virally encoded CD40L and the presence of CD40L protein in viral particles.

    abstract：:Expression of costimulatory molecules by recombinant poxviruses is a promising strategy for enhancing therapeutic vaccines. CD40-CD40L interactions are critical for conditioning dendritic cells (DC) and priming T- and B-cell immunity. We constructed a vaccinia virus expressing murine CD40L (rV-CD40L) and studied its i...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700762

    authors： Bereta M,Bereta J,Park J,Medina F,Kwak H,Kaufman HL

    更新日期：2004-12-01 00:00:00

  • Transduction of the IL-21 and IL-23 genes in human pancreatic carcinoma cells produces natural killer cell-dependent and -independent antitumor effects.

    abstract：:We examined whether novel cytokines, interleukin (IL)-21 and IL-23, that were expressed in tumors could produce antitumor effects in the inoculated mice. Human pancreatic cancer AsPC-1 cells were retrovirally transduced with murine IL-21 or IL-23 (p19-linked p40) gene (AsPC-1/IL-21, AsPC-1/IL-23) and were injected int...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700630

    authors： Ugai S,Shimozato O,Yu L,Wang YQ,Kawamura K,Yamamoto H,Yamaguchi T,Saisho H,Sakiyama S,Tagawa M

    更新日期：2003-10-01 00:00:00

  • Enhancing the cytotoxicity of chemoradiation with radiation-guided delivery of anti-MGMT morpholino oligonucleotides in non-methylated solid tumors.

    abstract：:The DNA repair enzyme O6-methylguanine DNA methyltransferase (MGMT) is epigenetically silenced in some tumors by MGMT gene promoter methylation. MGMT-hypermethylated solid tumors have enhanced susceptibility to the cytotoxic effects of alkylating chemotherapy such as temozolomide, compared with non-methylated tumors. ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2017.27

    authors： Ambady P,Wu YJ,Walker JM,Kersch C,Pagel MA,Woltjer RL,Fu R,Muldoon LL,Neuwelt EA

    更新日期：2017-08-01 00:00:00

  • Recombinant interferon alpha2a synergistically enhances ganciclovir-mediated tumor cell killing in the herpes simplex virus thymidine kinase system.

    abstract：:The herpes simplex virus thymidine kinase (HSV-TK) gene is being developed in the treatment of many different types of tumors. The HSV-TK gene sensitizes tumor cells to the antiviral drug ganciclovir (GCV) and mediates the bystander effect in which unmodified tumor cells are killed as well. Although this approach has ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700063

    authors： Whartenby KA,Darnowski JW,Freeman SM,Yurasha K,Calabresi P

    更新日期：1999-09-01 00:00:00

  • Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein.

    abstract：:We have described three potential adenovirus type 5 (Ad5)-based replication-competent cancer gene therapy vectors named KD1, KD3, and VRX-007. All three vectors overexpress an Ad5 protein named Adenovirus Death Protein (ADP, also named E3-11.6 K protein). ADP is required for efficient lysis of Ad5-infected cells and s...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700555

    authors： Toth K,Tarakanova V,Doronin K,Ward P,Kuppuswamy M,Locke JE,Dawson JE,Kim HJ,Wold WS

    更新日期：2003-03-01 00:00:00

  • Targeting HSV-1 virions for specific binding to epidermal growth factor receptor-vIII-bearing tumor cells.

    abstract：:Oncolytic herpes simplex virus (HSV) vectors have been used in early phase human clinical trials as a therapy for recurrent malignant glioblastoma. This treatment proved safe but limited improvements in patient survival were observed. The potency of these vectors might be enhanced by targeting vector infectivity to tu...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2010.22

    authors： Grandi P,Fernandez J,Szentirmai O,Carter R,Gianni D,Sena-Esteves M,Breakefield XO

    更新日期：2010-09-01 00:00:00

  • Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy.

    abstract：:B-cell malignancies upregulate the B-cell lymphoma 2 (Bcl-2) family inhibitors of the intrinsic apoptosis pathway, making them therapy resistant. However, small-molecule inhibitors of Bcl-2 family members such as ABT-737 restore a functional apoptosis pathway in cancer cells, and its oral analog ABT-263 (Navitoclax) h...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2013.35

    authors： Karlsson H,Lindqvist AC,Fransson M,Paul-Wetterberg G,Nilsson B,Essand M,Nilsson K,Frisk P,Jernberg-Wiklund H,Loskog A

    更新日期：2013-07-01 00:00:00

  • Oral contrast enhances the resolution of in-life NIS reporter gene imaging.

    abstract：:Sodium iodide symporter (NIS) reporter gene imaging is an excellent technology for noninvasive cell fate determination in living animals unless the NIS-transduced cells reside in perigastric organs such as the spleen, liver, diaphragm, omentum, pancreas, perigastric lymph nodes or perigastric tumor deposits. Here we r...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2013.57

    authors： Suksanpaisan L,Pham L,McIvor S,Russell SJ,Peng KW

    更新日期：2013-11-01 00:00:00

  • Adenovirus-mediated transfer of p53 and Fas ligand drastically enhances apoptosis in gliomas.

    abstract：:Various therapeutic approaches toward killing glioma cells by inducing apoptosis have been developed, but these approaches are often hampered by anti-apoptotic mechanisms. In this study, we attempted to develop a technique that overrides the resistance toward apoptosis in glioma cells. To date, p53- and Fas-mediated a...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700160

    authors： Shinoura N,Yoshida Y,Asai A,Kirino T,Hamada H

    更新日期：2000-05-01 00:00:00

  • Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.

    abstract：:Replication-selective oncolytic viruses are being developed for human cancer therapy. We previously developed an attenuated adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase promoter element drives expression of E1A and E1B genes linked with an internal ribosome entry site. OBP-301...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2012.57

    authors： Watanabe Y,Hashimoto Y,Kagawa S,Kawamura H,Nagai K,Tanaka N,Urata Y,Fujiwara T

    更新日期：2012-11-01 00:00:00

  • Glioblastoma: exosome and microRNA as novel diagnosis biomarkers.

    abstract：:Glioblastoma (GBM) is known as a tumor type, which arises from astrocytes. Several studies indicated that GBM tumor cells are malignant. This is because of the fact that they consist of different cell types, which are reproducing very quickly and are also supported by a large network of blood vessels. The correct iden...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章,评审

    doi：10.1038/cgt.2016.48

    authors： Saadatpour L,Fadaee E,Fadaei S,Nassiri Mansour R,Mohammadi M,Mousavi SM,Goodarzi M,Verdi J,Mirzaei H

    更新日期：2016-12-01 00:00:00

  • Use of monitoring levels of soluble forms of cytokeratin 18 in the urine of patients with superficial bladder cancer following intravesical Ad-IFNα/Syn3 treatment in a phase l study.

    abstract：:A phase l study using intravesical Ad-IFNαSyn3 for patients with bacillus Calmette-Guérin-resistant superficial bladder cancer showed a complete remission (CR) of 43% at 90 days after treatment with high levels of interferon-α (IFNα) being produced. Ad-IFNα kills bladder cancer cells by two apoptotic and one necrotic ...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/cgt.2014.1

    authors： Benedict WF,Fisher M,Zhang XQ,Yang Z,Munsell MF,Dinney CN

    更新日期：2014-03-01 00:00:00

  • Endostatin gene therapy delivered by attenuated Salmonella typhimurium in murine tumor models.

    abstract：:Salmonella typhimurium (hereafter S. typhimurium), as Gram-negative facultative anaerobic bacteria, are good candidates for cancer therapy and delivering therapeutic antitumor agents. However, it is necessary to reduce the virulence of such bacteria and enhance their tumor-targeting ability, and their immunostimulator...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/s41417-018-0021-6

    authors： Liang K,Liu Q,Li P,Han Y,Bian X,Tang Y,Kong Q

    更新日期：2018-08-01 00:00:00

  • Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.

    abstract：BACKGROUND:Interferon-gamma (IFN-gamma) gene/retroviral vector cell vaccinations have generated protective responses from unmodified tumor cell challenges as well as a regression of established tumors in animal models. The purpose of this trial was to determine the feasibility and safety of a direct intratumoral inject...

    journal_title：Cancer gene therapy

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.cgt.7700019

    authors： Nemunaitis J,Fong T,Robbins JM,Edelman G,Edwards W,Paulson RS,Bruce J,Ognoskie N,Wynne D,Pike M,Kowal K,Merritt J,Ando D

    更新日期：1999-07-01 00:00:00

  • Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.

    abstract：:Current oncolytic viruses exert only limited antitumor activity on their own. There is a need to increase their oncolytic capability. We evaluated the effect of a differentiating reagent, hexamethylene bisacetamide (HMBA), on the antitumor activity of a gamma(1)34.5-deficient herpes simplex virus type 1 (HSV-1) R849 f...

    journal_title：Cancer gene therapy

    pub_type： 杂志文章

    doi：10.1038/sj.cgt.7700957

    authors： Naito S,Obayashi S,Sumi T,Iwai S,Nakazawa M,Ikuta K,Yura Y

    更新日期：2006-08-01 00:00:00